Related Experiment Video
Updated: Jul 6, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Targeted therapies in the treatment of non-small cell lung cancer]
Jacques De Grève1, Lore Decoster, Jan Van Meerbeek
1Dienst Medische Oncologie, Oncologisch Centrum, UZ Brussel -VUB Laarbeeklaan 101, B-1090 Jette, Belgique. Jacques.degreve@uzbrussel.be
Abstract:
New targeted treatments offer an important opening towards the improvement of the results in the treatment of lung cancer. Currently two types of therapeutic targets are developed successfully in the treatment of advanced non-small cell lung cancer: tumour angiogenesis and growth factor receptors. Therapeutic drugs are small molecules inhibitors and the monoclonal antibodies. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor, VEGF, an important molecule in tumour angiogenesis. The combination of bevacizumab with first line chemotherapy increases the median survival of advanced NSCLC with a few weeks. At this moment no biomarker predicting efficacy that can help in the selection of patients is unfortunately available for this expensive treatment, although it is important to select patients based on specific contra-indications. The epidermal growth factor receptor (EGFR or HER1) is activated in NSCLC by several mechanisms. The small molecules erlotinib and gefitinib are targeting the intracellular kinase domain of the EGF receptor, thus inhibiting the signal transduction cascade. Erlotinib is currently registered and reimbursed in Belgium. The concomitant use of these small molecules with chemotherapy is ineffective in non-selected NSCLC patients. On the other hand, these molecules have great activity in patients with tumours having a constitutionally activated EGFR. Changes in the kinase domain of the receptor give rise to extremely high response rates and unexpectedly improved survival duration in patients with NSCLC. Currently studies are exploring whether erlotinib should be employed in the first line treatment of NSCLC. The FIELT study is a translational academic and multicentre phase II study in Belgium and Luxemburg addressing this issue. Specific mechanisms of resistance for these agents are gradually discovered and the new drugs being able to overcome these resistances are at the horizon.
Insights
Targeted therapies like bevacizumab and EGFR inhibitors show promise for advanced non-small cell lung cancer (NSCLC). Erlotinib demonstrates significant efficacy in patients with specific EGFR mutations, improving survival in lung cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment is improving with targeted therapies.
- Key targets include tumor angiogenesis and growth factor receptors, with drugs like bevacizumab and EGFR inhibitors.
- Bevacizumab, an anti-VEGF monoclonal antibody, offers modest survival benefits when combined with chemotherapy for advanced NSCLC.
Purpose of the Study:
- To evaluate the efficacy of targeted treatments in advanced non-small cell lung cancer.
- To investigate the role of epidermal growth factor receptor (EGFR) inhibitors, such as erlotinib, in NSCLC treatment.
- To explore the potential of erlotinib in first-line treatment for NSCLC, as investigated in the FIELT study.
Main Methods:
- Review of targeted therapies including monoclonal antibodies (bevacizumab) and small molecule inhibitors (erlotinib, gefitinib).
- Analysis of treatment outcomes for advanced NSCLC based on therapeutic targets like tumor angiogenesis and EGFR.
- Description of the FIELT study, a translational academic multicenter phase II study in Belgium and Luxembourg.
Main Results:
- Bevacizumab combined with chemotherapy offers a small increase in median survival for advanced NSCLC.
- Small molecule inhibitors targeting the EGFR kinase domain show high response rates and improved survival in NSCLC patients with specific EGFR mutations.
- Concomitant use of EGFR inhibitors with chemotherapy is ineffective in unselected NSCLC patients.
Conclusions:
- Targeted therapies, particularly EGFR inhibitors like erlotinib in mutation-positive NSCLC, represent a significant advancement in lung cancer treatment.
- Patient selection based on biomarkers is crucial for optimizing the use of expensive targeted treatments.
- Ongoing research, including studies like FIELT, aims to define the optimal role of erlotinib in first-line NSCLC therapy and address resistance mechanisms.
More Related Videos
07:59Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...